Posted by admin on Aug 7th, 2022
Royce & Associates LP grew its holdings in shares of Cytosorbents Co. (NASDAQ:CTSO – Get Rating) by 39.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 349,000 shares of the medical research company’s stock after buying an additional 98,000 shares during the quarter. Royce & Associates LP owned 0.80% of Cytosorbents worth $1,113,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in CTSO. GSA Capital Partners LLP bought a new position in shares of Cytosorbents during the fourth quarter valued at about $54,000. Cowen Prime Advisors LLC lifted its position in shares of Cytosorbents by 316.0% during the first quarter. Cowen Prime Advisors LLC now owns 15,600 shares of the medical research company’s stock valued at $50,000 after purchasing an additional 11,850 shares in the last quarter. Paradigm Financial Partners LLC bought a new position in shares of Cytosorbents during the fourth quarter valued at about $159,000. Raymond James Financial Services Advisors Inc. bought a new position in shares of Cytosorbents during the fourth quarter valued at about $199,000. Finally, Winning Points Advisors LLC bought a new position in shares of Cytosorbents during the first quarter valued at about $218,000. 40.98% of the stock is currently owned by institutional investors and hedge funds.
Separately, B. Riley dropped their price target on shares of Cytosorbents from $7.00 to $6.00 in a research report on Wednesday, May 4th.
Shares of CTSO stock opened at $2.10 on Friday. The firm has a market cap of $91.52 million, a price-to-earnings ratio of -2.56 and a beta of 0.37. Cytosorbents Co. has a 52 week low of $1.69 and a 52 week high of $9.80. The firm’s 50-day simple moving average is $2.14 and its two-hundred day simple moving average is $2.73.
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant.
Want to see what other hedge funds are holding CTSO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytosorbents Co. (NASDAQ:CTSO – Get Rating).
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.
New York State Common Retirement Fund Increases Stock Holdings in Avid Bioservices, Inc. (NASDAQ:CDMO)
Unique Fabricating, Inc. (NYSEAMERICAN:UFAB) Shares Sold by Royce & Associates LP